#JPM22: Highlights for the year ahead in oncology R&D — What's hot, what's not?
Across the broad spectrum of oncology drug development, 2021 marked a year of breakthroughs with off-the-shelf cell therapies coming into their own (with some questions) as classically “undruggable” targets fell to the inevitable march of progress.
In 2022, some of the brightest minds in oncology see the potential for even more breakthroughs — a revolution in epigenetics affording even more insight into the function of the cell, the potential for a major advance in AI-based discovery, and even more targets suddenly coming available to therapeutic intervention.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.